These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30452928)

  • 1. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study).
    Ong KL; Hui N; Januszewski AS; Kaakoush NO; Xu A; Fayyad R; DeMicco DA; Jenkins AJ; Keech AC; Waters DD; Barter PJ; Rye KA
    Metabolism; 2019 Apr; 93():93-99. PubMed ID: 30452928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis.
    Ong KL; Campbell S; Wu BJ; McClelland RL; Kokkinos J; Szklo M; Polak JF; Allison MA; Rye KA
    Atherosclerosis; 2019 Aug; 287():46-53. PubMed ID: 31212234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    PLoS One; 2014; 9(12):e114519. PubMed ID: 25531109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).
    Arsenault BJ; Kohli P; Lambert G; DeMicco DA; Laskey R; Messig MM; Kastelein JJ; Waters DD
    Am J Cardiol; 2016 Aug; 118(4):494-8. PubMed ID: 27328952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
    Byun YS; Lee JH; Arsenault BJ; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2015 Apr; 65(13):1286-1295. PubMed ID: 25835440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
    Ong KL; Januszewski AS; O'Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Rye KA; Keech AC;
    Diabetologia; 2015 Sep; 58(9):2035-44. PubMed ID: 26055067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
    Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ; Kastelein JJ; Lambert G
    J Am Coll Cardiol; 2012 May; 59(20):1778-84. PubMed ID: 22575316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
    Ong KL; Januszewski AS; O'Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Scott RS; Taskinen MR; Keech AC; Rye KA
    Diabetologia; 2015 Mar; 58(3):464-73. PubMed ID: 25425220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
    Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
    Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).
    Johnson C; Waters DD; DeMicco DA; Breazna A; Bittner V; Greten H; Grundy SM; LaRosa JC
    Am J Cardiol; 2008 Nov; 102(10):1312-7. PubMed ID: 18993147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
    Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
    Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
    Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
    Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ;
    Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
    Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ
    J Clin Lipidol; 2018; 12(2):356-366. PubMed ID: 29310989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events.
    Wu L; Qian L; Zhang L; Zhang J; Zhou J; Li Y; Hou X; Fang Q; Li H; Jia W
    J Am Heart Assoc; 2020 Jun; 9(11):e015226. PubMed ID: 32431189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
    Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B; Colman PG; Best JD; Simes JR; Rye KA; Keech AC;
    Clin Chem; 2017 Jul; 63(7):1261-1270. PubMed ID: 28606915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum FGF21 Is Associated with Future Cardiovascular Events in Patients with Coronary Artery Disease.
    Shen Y; Zhang X; Xu Y; Xiong Q; Lu Z; Ma X; Bao Y; Jia W
    Cardiology; 2018; 139(4):212-218. PubMed ID: 29462798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of circulating fibroblast growth factor 21 levels with pericardial fat: The Multi-Ethnic Study of Atherosclerosis.
    Magdas A; Ding J; McClelland RL; Allison MA; Barter PJ; Rye KA; Ong KL
    Sci Rep; 2019 Nov; 9(1):16423. PubMed ID: 31712677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.